Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | CCR3 | P51677 | 9/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016658 | 1.00 | SIGMAR1 (0.52) | SIGMAR1CCR3UBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL27228293 | 0.90 | SIGMAR1 (0.51) | SIGMAR1CCR3UBE2MDCUN1D1MCHR1 | |
| SCHEMBL31016690 | 0.90 | SIGMAR1 (0.51) | SIGMAR1CCR3UBE2MDCUN1D1MCHR1 | |
| SCHEMBL27228349 | 0.89 | PRKAA2 (0.51) | SIGMAR1CCR3MCHR1CHRM1 | |
| SCHEMBL27228677 | 0.89 | DPP7 (0.51) | SIGMAR1DCUN1D1POLBKMT2A | |
| SCHEMBL27228362 | 0.89 | SIGMAR1 (0.53) | SIGMAR1CCR3UBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL27228601 | 0.89 | SIGMAR1 (0.50) | SIGMAR1CCR3ALDH1A1POLBMCHR1 | |
| SCHEMBL31016697 | 0.89 | SIGMAR1 (0.50) | SIGMAR1CCR3ALDH1A1POLBMCHR1 | |
| SCHEMBL31016669 | 0.87 | MCHR1 (0.49) | CCR3MCHR1CHRM3 | |
| SCHEMBL27228329 | 0.87 | MCHR1 (0.49) | CCR3MCHR1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | claimed |
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | SIGMAR1 1/4885CCR3 2368/4885UBE2M 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.